Provention Bio, Inc. - Common Stock (NQ:PRVB)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Provention Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures ↗

July 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗

July 01, 2021

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...

Via Benzinga

20 Stocks Moving in Thursday's Pre-Market Session ↗

July 01, 2021

Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434...

Via Benzinga

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 29, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus ↗

June 27, 2021

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...

Via Benzinga

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes ↗

June 11, 2021

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-...

Via Benzinga

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 09, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

NASDAQ:PRVB Investor Notice: Lawsuit Alleges Securities Laws Violations by Provention Bio, Inc. ↗

June 08, 2021

San Diego, CA -- (SBWIRE) -- 06/08/2021 -- An investor, who purchased NASDAQ:PRVB shares, filed a against Provention Bio, Inc. over alleged violations of Federal Securities Laws.

Via SBWire

Topics Lawsuit

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 08, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Robbins Geller Rudman & Dowd LLP Announces Upcoming Lead Plaintiff Deadline in the Provention Bio, Inc. Class Action Lawsuit

June 07, 2021

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)

June 04, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 03, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)

June 02, 2021

From Law Offices of Howard G. Smith

Via Business Wire

PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

June 02, 2021

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 02, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders

June 01, 2021

From Robbins LLP

Via Business Wire

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

June 01, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

44 Biggest Movers From Friday ↗

June 01, 2021

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares jumped 95.7% to close at $7.81 on continued momentum after the company announced it will acquire an Alabama refinery and related...

Via Benzinga

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 31, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB

May 30, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

Why Provention Bio Stock Crashed Today ↗

May 28, 2021

An FDA advisory committee vote was a lot closer than anticipated.

Via The Motley Fool

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors

May 28, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 28, 2021

Gainers Organovo Holdings (NASDAQ:ONVO) stock moved upwards by 28.66% to $10.01 during Friday's regular session. Trading volume for this security as of 12:30 EST is 6....

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

May 28, 2021

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares surged 48.6% to $5.93 on continued momentum after the company announced it will acquire an Alabama refinery and related...

Via Benzinga

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 28, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 28, 2021

Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 21.13% to $1.49 during Friday's pre-market session. The company's market cap stands at $266.9...

Via Benzinga

The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq ↗

May 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,...

Via Benzinga

FDA Advisory Committee Votes In Favor Of Approval Of Provention Bio's Diabetes Med ↗

May 28, 2021

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of recommending approval of Provention Bio Inc’s (NASDAQ: PRVB...

Via Benzinga

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors

May 27, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.